Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of up to $200M of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Jefferies, Goldman Sachs & Co., Evercore Group, and Guggenheim Securities are acting as the joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $65 from $50 at Baird
- Spyre Therapeutics Reports Promising Trial Results for SPY001
- Spyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
- Spyre Therapeutics Advances IBD Treatment Pipeline
- Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
Questions or Comments about the article? Write to editor@tipranks.com